Melanoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have agreed to take part by signing the official consent form for this study
- People who have been diagnosed with melanoma at Stage II, III, or IV, whether it is a new diagnosis or the cancer has come back
- People whose doctors expect them to live for at least one year
- People who are planned to receive a type of cancer treatment called immune checkpoint inhibitor (ICI) therapy — either alone or combined with another treatment — before surgery, after surgery, or for melanoma that has spread
- For the women's group (Cohort 1): Women aged 18 to 45 years old at the time of signing the consent form
- For the women's group (Cohort 1): Women who are premenopausal, meaning their hormone levels (FSH) fall within the premenopausal range on a blood test. Women on hormonal contraception with an unusual FSH result may still be considered if another hormone level (AMH) is at or above a certain level on a blood test
- For the women's group (Cohort 1): Women whose AMH hormone level (a measure related to egg supply) is at or above a certain level on a blood test
- For the men's group (Cohort 2): Men aged 18 to 60 years old at the time of signing the consent form
- For the men's group (Cohort 2): Men whose hormone levels (testosterone, LH, and FSH) are all within the normal range on a fasting morning blood test
Who may not be able to join:
- Women who have had both ovaries surgically removed, or men who have had both testes surgically removed or have previously had a vasectomy
- People who are planned to receive, or have previously received, radiation therapy to the pelvic area
- People who have taken certain medications in the past 6 months that are known to affect reproductive hormones — for example, hormone-suppressing injections, certain breast cancer medications, testosterone, or anabolic steroids (confirm with trial site if unsure whether a specific medication applies)
- People who have received certain types of chemotherapy (alkylating or platinum-based) within the past 2 years
- People who have previously received immune checkpoint inhibitor (ICI) therapy
- People who have a history of a condition where the body does not produce enough sex hormones (hypogonadism)
- People who have any psychological, social, geographic, or other circumstances that the trial doctor believes could make participation not in the person's best interest, or that could affect the reliability of the study results
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Dr Wanda Cui, BMEDSCI, MBBS, Peter MacCallum Cancer Centre, Australia
Phone: +61 3 8559 5000
Australian sites
+61 3 8559 5000
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
6 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Change in ovarian reserve before, during and after ICI treatment; Change in testicular function before, during and after ICI treatment
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.